Royal Liverpool Clinical Research Unit performs first in human dermatology study ahead of schedule


The sponsor had developed a new drug as an alternative to steroid/ antibiotic treatment for patients suffering with severe eczema. The study was to begin with individuals having a single dose of the drug administered whilst in the research unit followed by dosing at home twice a day for two weeks. Eczema is a common skin condition amongst people within the North West area and the clinical research unit at the Royal was the only unit in the North West trialling the treatment. The study involved a two night stay on the research unit for each participant with meals provided and single patient room facilities.


The primary challenges the clinical research unit faced were:

  • Ensuring MHRA, ethical and trust approvals were in place as quickly as possible to ensure there were no delays in recruitment.
  • Recruiting a large cohort of participants for the study in a tight timeframe.
  • Participants had to be educated on how to dose themselves correctly whilst at home with a first in human drug.
  • Close monitoring between the study team and the trial participants had to be maintained to ensure safety whilst individuals were dosing outside of the clinical research unit.


MHRA and ethical requests for approvals were followed up regularly to ensure the study was able to start recruiting as soon as possible. The clinical research unit worked closely with their strategic partner ‘Covance’ to enable smooth communication between both sites and to eliminate delays in the study starting. Once both MHRA and ethics approval was received (on a Friday) the CRU team was quickly and efficiently able to update the Royal Liverpool Research and Development team of this and gain approval for the study to run the following Monday. Due to building up a database of patients utilising Consent4Consent prior to the study starting, we were then able to screen our first participant on the Tuesday (the day after R&D approval).

Participants were recruited from the dermatology clinics running across RLBUHT and through individuals directly contacting the research unit after seeing adverts and posters. Once confirmed as eligible each participant was provided with training on how to correctly apply the dose of the drug to their skin, and then assessed as competent by the clinical team prior to discharge. Safety reporting was emphasised and discussed prior to home dosing and participants were encouraged to contact the CRU in and out of hours with any issues or queries they may have. Participants had regular scheduled contact with the research staff to ensure they were happy to continue, and numerous assessments were carried out to ensure safety was maintained and that trial data was collected correctly.


The clinical research team were able to complete recruitment for the study 4 weeks ahead of the study schedule, and now have a cohort of dermatology patients who could be contacted regarding involvement in future studies.

The first two phases of the study have now been completed and all safety and trial data have been analysed.

The CRU and research staff received incredibly positive feedback from the trial participants, most of whom have signed up to the C4C database so that they can get involved in more research in the future.